Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) has a half-life of approximately one week, which means it takes roughly five weeks for the medicine to clear from your system after your last dose. That single pharmacokinetic fact shapes everything from how quickly side effects ease off to how long it takes for your appetite to return. Because semaglutide is a prescription-only medicine, any decision to stop, pause or restart treatment should be made with a prescriber rather than on your own timetable. Understanding the clearance window is genuinely useful — knowing what to expect in those five weeks can reduce anxiety and help you plan. You can read more about the full duration of action on our detailed page covering how long Wegovy stays in your system.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've given yourself your last Wegovy injection, perhaps because you want a break, you're heading abroad for a few weeks, or your prescription has run out. The pen is in the sharps bin. What happens next is determined by half-life chemistry, not by how you feel.
Semaglutide's half-life of around seven days means that roughly half the active medicine remains in your system after the first week, a quarter after the second, and so on. By week four or five, circulating semaglutide is below the threshold at which it meaningfully affects the GLP-1 receptor. The NHS semaglutide medicine page confirms this pharmacokinetic profile.
The practical implication: you will not feel a sudden cliff-edge on day one. Appetite suppression tends to ease gradually, usually becoming noticeably weaker by weeks one and two, while full clearance of the molecule trails behind that subjective change. If you are wondering how long Wegovy is out of your system before nausea or fatigue fully resolve, the answer is that these side effects often lift within days of the last dose as active levels begin falling, with digestive effects following a similar pattern.
For many people the two-week mark is when hunger feels meaningfully different — not necessarily overwhelming, but no longer blunted the way it was on treatment. That timing matters if you are trying to plan meals, shopping or travel around a pause.
In short, higher doses mean more medicine to clear, but the half-life stays the same. Whether you were on the standard 2.4 mg maintenance dose or the newer 7.2 mg dose approved by the MHRA in April 2026, semaglutide's molecular behaviour does not change. A higher starting concentration does mean there is more ground to cover before circulating levels reach negligible levels, so some people find the appetite and side-effect fade takes the fuller five weeks rather than four at higher doses.
The pace of titration on the way up has no bearing on how quickly the medicine leaves your system on the way down. Clearance is linear. If you want a concrete sense of the full duration of action, the page on how long Wegovy is in your system covers this in more detail.
One practical point worth knowing: if you stop mid-titration rather than at maintenance dose, clearance may feel faster because you started from a lower concentration. That does not mean the medicine is less effective or that restarting should skip dose steps, the titration schedule exists for tolerability reasons and your prescriber will guide any restart.
This is the question our prescribers hear most often when patients consider pausing. The honest answer is that for most people, appetite gradually returns to its pre-treatment baseline as semaglutide clears, and with it some of the weight lost during treatment can return. Clinical data from the STEP 1 trial, published in the New England Journal of Medicine, showed that participants who stopped semaglutide regained a substantial proportion of lost weight within a year.
That is not a reason to feel pessimistic; it is a reason to plan. If you are pausing for a defined period (a holiday, surgery, a financial pause) discussing a restart plan with a prescriber before you stop gives you something to come back to. If cost is part of the equation, the page on Wegovy prices sets out what to expect from private treatment.
Worth noting: if you are asking how long till Wegovy is out of your system before weight starts returning, the weight-return dynamic is slower than the clearance timeline, since appetite comes back within two weeks but meaningful weight change from appetite alone takes longer than that. The five-week window is the pharmacological story; lifestyle and dietary habits fill in the rest.
If you are planning to stop Wegovy temporarily (say, over the Christmas break, or because payday timing means a gap in your supply) it is worth knowing that missing a single dose is very different from a deliberate multi-week pause. One missed week is unlikely to reset your appetite significantly. Several weeks off will. Restarting after a break of more than a few weeks typically means returning to a lower dose step, not jumping back to where you were, because the GI tolerability pattern effectively resets.
For people who are considering switching from Wegovy to tirzepatide, the five-week clearance window does not necessarily mean a five-week wait. Switching timelines depend on clinical assessment. Our weight-loss treatment overview explains both licensed options available in the UK, and if you have a specific question about how semaglutide clearance interacts with a planned switch, the semaglutide clearance timeline page goes further on the pharmacokinetics. A prescriber, not a general article, is the right person to confirm exact timing for your circumstances, you can check your eligibility with our clinical team if you are weighing your next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.